{"id":"W2601517348","doi":"10.1200/jco.2012.30.15_suppl.4047","title":"Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Temsirolimus; Internal medicine; Everolimus; Mucositis; Bevacizumab; Interim analysis; Sunitinib; Clinical endpoint; Oncology; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Leukopenia; Progression-free survival; Adverse effect; Progressive disease; Rash; Surgery; Chemotherapy; Clinical trial; Cancer; PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.00254166,0.000224477,0.003411012,0.0008190561,0.00002466565,0.000005077726,0.0002611503,0.00003214824,0.000051843],"category_scores_gemma":[0.02361773,0.0001596176,0.0006550627,0.0005579595,0.0004475194,0.0002216696,0.0002133352,0.001173938,0.000002217747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007422032,"about_ca_system_score_gemma":0.0004036038,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005507823,"about_ca_topic_score_gemma":0.00006193461,"domain_scores_codex":[0.99221,0.001245566,0.005093082,0.0002816542,0.0006281484,0.0005415669],"domain_scores_gemma":[0.9898083,0.005608625,0.003193612,0.0003801943,0.0003442775,0.0006650019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8917475,0.02939797,0.04882414,0.0001625008,0.001216807,0.007591667,0.0001381454,0.00002093199,0.002616716,0.00001414605,0.0005901873,0.01767927],"study_design_scores_gemma":[0.6028988,0.2314047,0.1435864,0.0002905018,0.002468841,0.002769357,0.0002359011,0.0005315581,0.002858033,0.0000289761,0.01275238,0.0001745797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995588,0.0004129443,0.000007087178,0.002328468,0.0005712865,0.000679679,0.00002508061,0.000006782527,0.0003806858],"genre_scores_gemma":[0.9973462,0.0005459293,0.0009691119,0.0002940442,0.00068363,0.000007284999,0.000006411204,0.00002105569,0.000126321],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2888487,"threshold_uncertainty_score":0.9846067,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1189870199043359,"score_gpt":0.4999713452551495,"score_spread":0.3809843253508136,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}